Kuria Therapeutics, a pharmaceutical company developing a platform of novel NRF2 activators for ophthalmic disease, will be holding meetings with investors and other parties during the 44th Annual J.P. Morgan Healthcare Conference, January 11-15 2026, in San Francisco, California. Kuria's Chief Executive Officer, Dr. Keith Ward, will be holding one-on-one meetings during the conference to discuss the latest company and data updates for Kuria's lead program transforming treatm

SCOHIA PHARMA and Kuria Therapeutics Announce Issuance of Key Patent Covering Novel Nrf2 Activator KANAGAWA, Japan & LITTLE ROCK,...

Kuria Therapeutics and SCOHIA PHARMA Announce Strategic Licensing Agreement for Ophthalmic and Dermal Rights to SCO-116, A Novel Nrf2...